Tests encapsulated pig islet cells in adults with unstable type 1 diabetes

Trial details

Who runs it

Otsuka Pharmaceutical Factory, Inc.

Trial code

NCT06575426

Record updated

21 August 2026

Original description

This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.Read full original descriptionShow less

A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus

This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.

Inclusion: Subject must be aged 35 to 70 years of age inclusive, at the time of signing the informed consent; Subject has an established diagnosis of type 1 diabetes mellitus (T1DM) (in accordance with the American Diabetes Association's criteria), with a minimum duration since diagnosis of 5 years; If one of the following criteria (either a or b) applies:; Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G6, insulin pump: Omnipod® 5 or t:slim X2) under care of a qualified diabetes team for at least 6 months prior to enrollment; Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G7, insulin pump: Omnipod® 5, t:slim X2, iLet Bionic Pancreas or The Tandem Mobi System) under care of a qualified diabetes team for at least 6 months prior to enrollment; If one of the following criteria (either a, b or c) applies:; Subject has had a Level 3 (severe) hypoglycemic episode (defined as having cognitive impairment requiring external assistance for recovery) at least three times within the 1 year prior to enrollment recorded in the medical record or patient log; Subject has had a Level 3 (severe) hypoglycemic episode at least once within the 1 year prior to enrollment and demonstrates a Clarke Score ≥4, assessed by trained study personnel. The SHE(s) and Clarke Score must be recorded in the medical record or patient log; Subject has had TBR >1% at glucose levels below 70mg/dL and demonstrates a Clarke Score≥4, assessed by trained study personnel. TBR data used for screening and Clarke score must be recorded in the medical record or patient log; Subject has C-peptide <0.3 ng/mL following a mixed meal tolerance test or undetectable fasting C-peptide; Hemoglobin A1C (HbA1c) ≤ 9.0; Contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Subject who can agree to cooperate with lifetime follow-up after transplantation; Subject is capable of providing signed informed consent.

Exclusion: Previous history of insulin resistance (defined as an average insulin dose requirement ≥ 0.8 unit/kg/day for 1 week prior to enrollment); Adrenal insufficiency being treated with corticosteroids; Previous pan-peritonitis; Previous cardiovascular or cerebrovascular disease. NOTE: For the purposes of this exclusion criterion, "previous cardiovascular disease" is defined as the presence of co-existing cardiac disease, characterized by any of the following conditions:; Recent myocardial infarction (within past one year), or; Angiographic evidence of non-correctable coronary artery disease, or; Evidence of ischemia on functional cardiac exam (with a stress echo test recommended for subjects with a history of ischemic disease), or; Heart failure > NYHAII For subjects aged 65 to <70 years who do not meet Exclusion Criterion 12 but have a history of cardiovascular or cerebrovascular disease related to the conditions above, a cardiology consultation (and consultation with other relevant specialists, as appropriate) will be required during the screening period to confirm suitability for general anesthesia and laparoscopic surgery; Patients who received a blood transfusion in the previous 90 days, are anticipated to undergo surgery during the 1-year study period that may require transfusion, or have donated blood within the previous 90 days; Previous receipt of an organ, skin allograft, or other tissue transplant from an allogeneic human or animal donor; Treatment with immunosuppressive medication; Previous abdominal surgery, excluding uncomplicated appendectomy, cholecystectomy, exploratory laparoscopy and hernia repair performed prior to 12 weeks prior to enrollment; Treatment with any hypoglycemic medication prescribed for glycemic control, other than insulin therapy; Treatment with acetaminophen or hydroxycarbamide; Use of any investigational products within 12 weeks of enrollment (before entering run-in) or 5 half-lives of the investigational product, whichever is greater; Previous history of insulin allergy (including porcine insulin), pork product allergy or alginate/seaweed allergy; Panel reactive antibodies (PRA) > 80 %; Active drug, substance or alcohol addiction; Subject has latent autoimmune diabetes in adults (LADA), ketosis-prone (Flatbush) diabetes, or maturity onset diabetes of the young (MODY); Clinically unstable thyroid disease (thyroid stimulating hormone (TSH)< the lower limit of the normal range of TSH at the site.) Patients with subclinical hyperthyroidism can be rescreened once TSH levels normalize due to treatment or other factors; History of malignancies within the past 5 years, excluding basal and squamous cell carcinoma; Positive serologies or nucleic acid testing for human immunodeficiency virus (HIV), hepatitis C, and hepatitis B; Patients with hematopoietic stem cell abnormalities (e.g., aplastic anemia, myelodysplastic syndrome); Subject has history of allergy to antibiotics (Amphotericin B, Cefazolin, Ciprofloxacin, Gentamicin), which are used during manufacture of OPF-310; Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol, including dementia, psychiatric disorder, medical condition, or a history of non-adherence to appointments or treatments; Serious comorbid conditions that are likely to affect participation in the study, including:; Within the last 12 months, peripheral vascular disease with previous amputation; History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation; Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalization for decompensation; a requirement for mechanical ventilation at any stage; or long- term treatment with oral corticosteroids; Macroalbuminuria (> 300 mg albumin/gm creatinine); Estimated glomerular filtration rate (eGFR) cut-off of < 30 ml/min for all per Kidney Disease Improving Global Outcomes (KDOQI) and Kidney Disease Outcomes Quality Initiative (KDIGO) consensus; Use of warfarin or other anticoagulant therapy (except aspirin), or prothrombin time and international normalized ratio (PT-INR) > 1.5; CRP ≥ 10 mg/L; Active or untreated proliferative diabetic retinopathy. Subjects may be rescreened once they are successfully treated; Body mass index (BMI) >27 kg/m2.

ClinicalTrials.gov NCT06575426